As well, a reduced enrichment of ‘TNF‐α signalling via NFκB’ was also observed in iCAFs from non‐responders, compared to iCAFs from responders, in pan‐cancer scRNA‐seq landscape of ICI therapy (Figure 6H). The gene discussed is NFKB1; the disease is cancer.